In conclusion, FGF-23 is likely signaling a worse health status in the FGF-23 upper-level group, since this group presented significantly more comorbidities (DM, CKD, previous MI and stroke) and more importantly, higher inflammation (higher CRP) and especially lower eGFR. This evidence concerns the gene CRP and chronic kidney disease.